相关实验视频

Updated: Jun 21, 2025

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

在HBeAg阴性慢性乙型肝炎患者中停止使用核类相应物:风险和益处

Pınar Korkmaz¹, Neşe Demirtürk²

¹Department of Infectious Diseases and Clinical Microbiology, Kütahya Health Sciences University School of Medicine, Kütahya, Türkiye.

Infectious diseases & clinical microbiology

|July 15, 2024

概括

在HBeAg阴性患者中,切断慢性乙型肝炎 (CHB) 的核酸类比 (NA) 治疗是可能的,但需要对患者进行仔细的选择和监测,以确保安全管理和潜在的HBsAg损失.

科学领域:

肝病学肝病学是一种肝病学.
病毒学病毒学
公共卫生公共卫生

背景情况:

慢性乙型肝炎 (CHB) 影响全球2.96亿人,目前的治疗方法可以控制但不能治愈病毒.
核酸相似物 (NA) 很少达到HBsAg损失 (1%),通常需要对HBeAg阴性患者进行终身治疗.
最近的指导方针表明,在HBeAg阴性患者中,NA的中止是可能的,但缺乏对管理的共识.

研究的目的:

审查当前关于在HBeAg阴性CHB患者中中止NA治疗的文献.
为了确定患者的个人资料,具有更高的可能性的积极结果后的NA停止.
探索NA停止后的复发模式和管理策略.

主要方法:

关于在HBeAg阴性CHB中中止NA的研究的文献综述.
分析影响治疗反应和NA停止后复发的因素.
与不同NA药物的复发率进行比较,包括恩特卡维尔和诺福维尔迪普西尔.

主要成果:

患有低HBsAg,HBcrAg和HBVRNA水平的非肝硬化HBeAg阴性CHB患者可能会在NA停药后反应更好.
与其他NA疗法相比,安特卡维尔的使用与更慢,更少的复发有关.
停药后复发和潜在恶化的管理仍然不清楚.

结论:

仔细选择HBeAg阴性CHB患者进行NA停药至关重要.
需要密切跟进和开发停产后管理算法.
需要进行进一步的前性研究,以优化HBsAg清除策略和管理急性恶化.

关键词:

在 HBeAg 阴性.这就是HBsAg.核子 (t) 化物类似物标题标题标题标题治疗治疗治疗治疗治疗治疗撤回撤回撤回撤回

更多相关视频

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

相关概念视频

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Hepatic Drug Excretion: Enterohepatic Cycling

Hepatic Drug Excretion: Enterohepatic Cycling

Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...